Centene (CNC) vs Progyny (PGNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Centene (CNC) has outperformed Progyny (PGNY) over the past year, gaining 69.2% versus a gain of 37.8%. Over five years, CNC leads with a -0.5% price change compared with -50.8% for PGNY. Centene is the larger company by market cap ($31.51 billion vs $2.08 billion), about 15.2 times the size.
On valuation, Progyny trades at a lower forward P/E (11.7x vs 11.9x for Centene).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNC | PGNY |
|---|---|---|
| Share price | $63.78 | $27.05 |
| Market cap | $31.51B | $2.08B |
| 1-day change | -1.86% | -1.81% |
| YTD return | +57.93% | +7.28% |
| 1-year return | +69.16% | +37.75% |
| 5-year return | -0.51% | -50.79% |
| P/E ratio (TTM) | — | 29.40 |
| Forward P/E | 11.93 | 11.66 |
| EPS (TTM) | $-10.44 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $194.78B | — |
| Revenue growth (YoY) | +19.44% | — |
| Net income (latest FY) | $-6.67B | — |
| Gross margin | 7.30% | — |
| Operating margin | -3.91% | — |
| Net margin | -3.43% | — |
| 52-week high | $69.63 | $33.07 |
| 52-week low | $31.63 | $16.10 |
| Distance from 52-week high | -8.40% | -18.19% |
| Analyst consensus | buy | none |
| Avg. price target upside | +12.54% | +27.25% |
| Average volume | 4.57M | 1.14M |
| Shares outstanding | 494.00M | 76.73M |
| Employees | 61,100 | 835 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Centene is about 15.2 times larger than Progyny by market value ($31.51B vs $2.08B).
- CNC has outperformed PGNY by 31.4 percentage points over the past year.
About Centene
CNC stock →Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other.
Health Care · Medical Specialities · 61,100 employees
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
CNC vs PGNY FAQ
Which is bigger, Centene or Progyny?
Centene (CNC) is larger, with a market capitalization of $31.51B compared with $2.08B for Progyny (PGNY).
Which stock has performed better over the past year, CNC or PGNY?
CNC returned +69.16% over the past 12 months, compared with +37.75% for PGNY (price return, excluding dividends). Past performance does not predict future results.
Are Centene and Progyny in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Centene and Misc Health and Biotechnology Services for Progyny.